BioAdvance

BioAdvance Capital is an evergreen, early-stage life sciences investor based in Conshohocken, PA, with approximately $70 million in assets. The fund targets seed and Series A companies headquartered along the I-95 corridor between New York City and Washington, D.C., with a requirement that the CEO be based in the region. BioAdvance invests exclusively in human health, spanning therapeutics, medical devices, digital health, diagnostics, and research tools. Initial check sizes range from $500K to $1.5M, with the ability to commit up to $5M over the life of a company; the fund can lead rounds between $500K and $5M. As an evergreen vehicle, BioAdvance does not operate on a traditional fundraising cycle. The fund has backed over 120 companies, achieved 28 exits, supported 12 FDA-approved products, and its portfolio has attracted more than $4.4 billion in follow-on capital.